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Abstract 
Background: The aim of this study was to analyze the oncological aspects of gastric cancer following laparoscopic 
gastrectomy with D2 lymphadenectomy (LG-D2).
Methods: We retrospectively evaluated the long-term outcomes of 354 patients who underwent LG-D2 for primary 
gastric cancer. Recurrence patterns and predictors of peritoneal metastasis were analyzed.
Results: Median follow-up time was 43.8 months. Five-year overall survival rates for yp/pStages I, II, and III gastric 
cancer were 93.7, 78.5, and 42.2 %, respectively. Recurrence was observed in 86 patients. Peritoneal metastasis was the 
most frequent recurrence pattern (n = 51), followed by hepatic metastasis (n = 17). Lymphatic recurrence at distant 
sites was observed in 10 patients. No locoregional lymph node metastasis or local recurrence was seen. Nine of 51 
cases of peritoneal recurrence were detected by probe laparoscopy. Peritoneal recurrence rates were significantly 
higher in yp/pT4 and yp/pN3 diseases compared with yp/pT ≤ 3 and yp/pN ≤ 2 diseases. Multivariate analyses dem-
onstrated that yp/pT4, yp/pN3, tumor size ≥70 mm, vascular invasion, and undifferentiated tumors were predictors of 
peritoneal recurrence following LG-D2.
Conclusion: Long-term outcomes of gastric cancer following LG-D2, including recurrence patterns and predictors of 
peritoneal metastasis, were comparable to those following open D2 gastrectomy. LG-D2 showed good local control. 
Probe laparoscopy after LG may be effective in detecting peritoneal recurrence, which is not determined with less 
invasive examinations, including a CT scan. Future large-scale prospective studies are desirable to evaluate not only 
surgical but also oncological benefits and safety of LG-D2 for advanced gastric cancer.
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Background
The first report of a laparoscopic distal gastrectomy 
(LDG) for gastric cancer was described by Kitano et  al. 
(1994). A number of randomized controlled trials (Kim 
et  al. 2010; Katai et  al. 2010) have reported equivalent 
short-term outcomes, including the incidence of anas-
tomotic leakage and a pancreatic fistula, following LDG 
with D1+ lymphadenectomy for ≤cT2N0 gastric cancer 
to those following an open distal gastrectomy (ODG), at 
least as long as LDG was performed by an experienced 
laparoscopic surgeon. Regarding ODG, previous studies 
(Degiuli et  al. 2010; Songun et  al. 2010) have reported 
that D2 lymphadenectomy reduces local recurrence and 
improves long-term outcomes compared with D1 lym-
phadenectomy in patients with advanced gastric cancer.
Laparoscopic gastrectomy with D2 lymphadenectomy 
(LG-D2) is currently performed for the treatment of 
advanced gastric cancer at some specialized institutions 
(Huscher et al. 2005; Cai et al. 2011). Concerning short-
term outcomes, recent meta-analyses (Zeng et  al. 2012; 
Zou et al. 2014; Huang et al. 2014) have reported no sig-
nificant difference in the number of harvested lymph 
nodes (LN) between ODG and LDG. However, detailed 
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studies assessing recurrence patterns and long-term out-
comes following LG-D2 are lacking.
In 1999, we reported on the technical aspects of LDG 
with D2 lymphadenectomy (LDG-D2) and laparoscopic 
total gastrectomy with D2 lymphadenectomy (LTG-D2) 
(Uyama et  al. 1999a, b) as well as short- and long-term 
outcomes following LG for gastric cancer (Yoshimura 
et al. 2011; Shinohara et al. 2013). In this study, we ret-
rospectively analyzed long-term outcomes of 346 gastric 
cancer patients who underwent LG-D2, especially focus-
ing on the recurrence pattern.
Methods
Patients
LG-D2 was performed in 369 consecutive cases of 
patients with cStage  ≥  IB gastric cancer at the Fujita 
Health University Hospital between August 1997 and 
December 2011. Preoperative chemotherapy (PC) was 
performed for 139 of the 369 patients. Of the 369 identi-
fied cases, 15 patients were diagnosed with yp/pStage IV 
of the disease. These 15 yp/p Stage IV patients included 
three with P0CY1, P1CY0, and H1 and six with M1 gas-
tric cancer, and they were excluded. Consequently, a 
clinical database containing the data of these 354 patients 
who underwent an R0 resection by LG-D2 for yp/pStages 
0–III gastric cancer were retrospectively reviewed. The 
pathological cancer stage was determined according to 
the 14th edition of the Japanese Classification of Gastric 
Carcinoma (2011a).
Indication and regimen of preoperative chemotherapy (PC)
After July 2005, Neoadjuvant chemotherapy was used for 
patients who were diagnosed with ≥cT2 or ≥cN1 gastric 
cancer and who agreed with a PC treatment. For these 
patients, S-1 (80 mg/m2) was administered from Day 1 to 
Day 21, CDDP (60 mg/m2) was injected on Day 8, and a 
2 week washout period was provided. This 5-week regi-
men was performed twice with 2 more weeks of wash-
out period before surgery. Induction chemotherapy 
(S-1 80 mg/m2 Day 1–14 + CDDP 35 mg/m2 Day 8, or 
Docetaxel 30 mg/m2 Day 1, 15 + CDDP 30 mg/m2 Day 
1, 15 +  S-1 80  mg/m2 Day 1–14) was used for StageIV 
disease diagnosed by probe laparoscopy or cytology, and 
radical gastrectomy was conducted when downstaging 
was achieved. Although downStaging was achieved for 7 
of 10 Stage IV patients, they were excluded as Stage IV 
because P1 or Cy1 was diagnosed pathologically via stag-
ing laparoscopy before chemotherapy.
Definition of D2 lymphadenectomy
The extent of gastric resection and LN dissection in LDG-
D2 and LTG-D2 were determined according to the 2010 
Japanese Gastric Cancer Treatment Guidelines (2011b). 
Accordingly, in LDG-D2, LN stations 1, 3, 4sb, 4d, 5, 6, 
7, 8a, 9, 11p, and 12a were dissected. In addition to those 
LN stations, LN stations 2, 4sa, 10, and 11d were dis-
sected in LTG-D2. Regarding the extent of splenic hilar 
LN dissection, a D2 lymphadenectomy combined with a 
distal pancreaticosplenectomy (D2 + PS) was performed 
in patients with tumors infiltrating into the pancreatic 
body or tail. A D2 lymphadenectomy combined with a 
splenectomy (D2  +  S) was performed in patients with 
LN metastasis at station 11d or 10, or in patients with a 
greater curvature invasion. A spleen-preserving D2 lym-
phadenectomy (D2-S) was performed in patients with 
tumor depths ≥cT3 without LN metastasis at station 11d 
or 10, whereas a D2 lymphadenectomy with preservation 
of station 10 LNs, and the spleen (D2-10) was performed 
in patients without a greater curvature invasion and with 
tumor depths ≤cT2 (Nakauchi et al. 2015).
Perioperative management, postoperative chemotherapy, 
and oncologic follow up
Most of our LG perioperative management details have 
been previously reported (Shinohara et  al. 2013; Suda 
et al. 2015). From 1997 to December 2004, some patients 
with pStage II/III gastric cancer received adjuvant chemo-
therapy, but the indication and regimen were not defined 
during this period. After Jan 2005, patients with yp/pStage 
II or III cancer received S-1-based adjuvant chemo-
therapy for 1  year and those with yp/pStage IV cancer 
received S-1-based definitive chemotherapy according 
to the 3rd Edition of the Japanese Gastric Cancer Asso-
ciation Guidelines ( 2011b). Patients with ypStage I gastric 
cancer also received S-1 based adjuvant chemotherapy for 
1 year when a Grade ≥ Ib pathological response of PC was 
observed. Regarding oncologic follow up, the discharged 
patients visited our outpatient clinic at least after 1 month, 
3 months, and then every 6 months until 5 years after sur-
gery. In the outpatient clinic, regular laboratory with car-
cinoembryonic antigen and carbohydrate antigen 19-9 
and physical examinations were performed. The patients 
were examined by chest and abdominopelvic computed 
tomographic (CT) scans every 6  months to detect any 
local recurrence and systemic metastasis. An upper gas-
trointestinal endoscopy was done every year to detect any 
local recurrence and metachronous multicentric or mul-
tiple cancers. Ultrasonography (US), magnetic resonance 
imaging (MRI), positron emission tomography-CT (PET-
CT), or scintigraphy was used in combination when nec-
essary. Peritoneal metastasis was definitively diagnosed by 
ascitic cytology or probe laparoscopy.
Definition of the recurrence pattern and survival time
The recurrence pattern was determined according to the 
primary recurrence site diagnosed by imaging studies 
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(CT, US, MRI, scintigraphy, or PET-CT), ascitic cytology, 
or probe laparoscopy. Locoregional LN metastasis was 
defined as the presence of lymphatic metastases within 
the D2 lymphadenectomy area. Distant LN metastasis 
was defined as the presence of any LN metastasis out-
side the area dissected by a D2 lymphadenectomy. Local 
recurrence was defined as the presence of non-lymphatic 
cancer tissue within the surgical area, residual stom-
ach, or anastomotic site. Hematogenous metastasis was 
defined as the presence of any distant metastasis, except 
hepatic metastases. In case multiple metastases patterns 
occurred simultaneously, the dominant metastasis was 
determined based on the number and size of the meta-
static lesions. Recurrence-free survival (RFS) was defined 
as the period from initial surgery to the first detection of 
recurrence or whatever was the cause of death. Survival 
after recurrence (SAR) was defined as the period from 
the first detection of recurrence to the time of death. 
Overall survival (OS) was defined as the period from ini-
tial surgery to the time of death. Censoring may occur if a 
patient reached the planned end of the study or was lost 
to follow-up.
Multivariate analysis of peritoneal recurrence‑free survival
Multivariate analysis of peritoneal recurrence-free sur-
vival was performed to determine the predictive factors 
for peritoneal metastasis. Peritoneal recurrence-free 
survival was defined as the period from initial surgery to 
the first detection of peritoneal recurrence or death. Pre-
dictive factors evaluated were age (≤64 or ≥65), gender 
(male or female), body mass index (≤21.0, 21.0–25.0, or 
>25.0), presence of comorbidities (yes or no), previous 
operations (yes or no), American Society of Anesthesi-
ologists’ **Classification (Class ≤2 or Class 3), preopera-
tive chemotherapy (yes or no), histological tumor type 
(differentiated or undifferentiated), tumor size (<70 or 
≥70 mm), T factor (≤T3 or T4), N factor (≤N2 or N3), 
lymphatic invasion (positive or negative), vascular inva-
sion (positive or negative), and operative procedure 
(LDG or LTG). Each factor was divided into two or three 
categories.
Statistical analyses
All statistical analyses were performed using the Statisti-
cal Package for Social Sciences (SPSS) version 19.0J for 
Windows (SPSS Inc., Chicago, Illinois, USA). Independ-
ent continuous variables were compared by the Mann–
Whitney U test or Kruskal–Wallis test, and categorical 
variables were compared by the χ2 (Chi-square) test or 
Fisher’s exact test. Long-term outcomes were analyzed 
using Kaplan–Meier methods with the log-rank test and 
Cox regression. Univariate analyses were performed for 
all potentially confounding variables and effect modifiers. 
Considering the relatively small sample size, all variables 
with a significant level of p < 0.05 in the univariate analy-
sis were included as independent variables.
Results
Clinical characteristics and survival rates
Clinical characteristics of the 354 analyzed patients are 
summarized in Table 1. Mean age was 62.6 ± 10.3 years. 
One or more comorbidities and prior abdominal surgery 
were identified in 174 patients (49.2  %) and 46 patients 
(13.0  %), respectively. Preoperative chemotherapy was 
performed for 128 patients. A total of 251 patients 
underwent LDG and 103 patients underwent LTG. The 
proportion of patients who underwent LTG was 29.1  % 
of all analyzed patients. Of the 103 patients who under-
went LTG, splenectomy was performed in 61 patients, 
of which a combined distal pancreatectomy was per-
formed in 22 patients. Combined resection of the trans-
verse colon to achieve an R0 resection was performed in 
one patient who underwent LDG and two patients who 
underwent LTG. The mean tumor size in patients who 
underwent LTG was significantly greater than in patients 
who underwent LDG (p < 0.001). A pathologically com-
plete response was observed in eight patients who under-
went PC. The yp/pT ≥  2 and yp/pN ≥  1 diseases were 
diagnosed in 222 patients (62.7  %) and 154 patients 
(43.5 %), respectively. The median follow-up period was 
43.8 months. During the observation period, 71 patients 
(20.1 %) died of gastric cancer and eight patients (2.3 %), 
including one patient (0.3  %) who died due to opera-
tive complications, died from other causes. Censoring 
occurred in 22 patients (6.2 %) within 5 years. OS curves 
according to the disease stage are shown in Fig. 1. 5-year 
OS rates stratified by yp/pStage I, II, and III were 93.7, 
78.5, and 42.2 %, respectively.
Recurrence patterns, RFS, SAR, and OS
During the follow-up period, gastric cancer recurrence 
was observed in 86 of the 354 patients (24.3 %). The most 
frequent recurrence pattern was peritoneal metastasis, 
which was observed in 51 patients (59.3 %), followed by 
hepatic metastasis, which was observed in 17 patients 
(19.8 %). Hematogenous metastasis was observed in eight 
cases (9.3 %). Distant lymphatic recurrence was observed 
in 10 cases (11.6  %). Neither locoregional lymphatic 
recurrence nor local recurrence in the D2 dissection 
area was observed. In 11 patients, a postoperative probe 
laparoscopy was performed to confirm peritoneal recur-
rence. Consequently, in nine cases, peritoneal recurrence 
was detected by probe laparoscopy as the first recurrence 
site. The SAR of patients with peritoneal recurrence was 
significantly shorter than that of patients with distant 
lymph node recurrence (p  =  0.012) (Table  2). Multiple 
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metastasis patterns were observed in eight (9.3 %) of the 
86 patients at the initial recurrence, each pattern is sum-
marized in Table 3.
The incidences of recurrence according to the disease 
stage and recurrence pattern are shown in Fig.  2a. The 
recurrence rate of peritoneal (p  <  0.001) and hepatic 
(p  <  0.001) metastasis was elevated in correspondence 
with the yp/pStage. Further, the recurrence rate of peri-
toneal metastasis in yp/pT4 gastric cancer cases was sig-
nificantly greater than in yp/pT ≤ 3 gastric cancer cases 
(p  <  0.001). Additionally, the rate of peritoneal metas-
tasis in yp/pN3 gastric cancer cases was significantly 
greater than in yp/pN ≤ 2 gastric cancer cases (p < 0.001, 
Fig. 2b).
RFS curves according to the yp- and p-stage are shown 
in Fig. 3. Recurrence was not observed in any of the eight 
patients with a complete pathological response to PC 
within 5 years. The clinical Stages of those eight patients 
were as follows: cStage I, 1; cII, 3; and cIII, 4. There was 
no significant difference between the RFS curves of “p-” 
and “yp-” between each Stage.
In 33 of the 51 patients with peritoneal metastasis, 
recurrence was diagnosed on the basis of CT findings. 
Twenty-one (63.6  %) of these 33 patients underwent 
Table 1 Clinical characteristics of patients (n = 354)
Values in parentheses are percentages unless otherwise indicated
PC preoperative chemotherapy, CR pathological complete response to PC, ASA American Society of Anesthesiologists, LDG laparoscopic distal gastrectomy, LTG 
laparoscopic total gastrectomy
a Values expressed as the mean ± SD
Variables Patients with PC  
(n = 128)
Patient without PC  
(n = 226)
All patients  
(n = 354)
Age (y/o)a 63.0 ± 9.5 62.4 ± 10.8 62.6 ± 10.3
Gender (male:female) 96: 32 148: 78 244: 1110
Body mass index (kg/m2)a 22.4 ± 3.4 21.9 ± 3.1 22.1 ± 3.2
Comorbidity: n (%) 63 (49.2) 111 (49.1) 174 (49.2)
Prior operations: n (%) 14 (10.9) 32 (14.2) 46 (13.0)
ASA: n (%)
 Class 1 62 (48.4) 110 (48.7) 172 (48.6)
 Class 2 50 (39.1) 96 (42.5) 146 (41.2)
 Class 3 16 (12.5) 20 (8.8) 36 (10.2)
Tumor size (mm)a 48.0 ± 33.0 39.3 ± 24.4 42.4 ± 28.1
Type of resection: n (%)
 LDG 74 (57.8) 177 (78.3) 251 (70.9)
 LTG 54 (42.2) 49 (21.7) 103 (29.1)
Harvested lymph nodes (n)a 43.8 ± 15.3 44.6 ± 15.9 44.3 ± 15.7
Pathological status (yp/p): n (%)
 CR 8 (6.3) 0 (0) 8 (2.3)
 T1 24 (18.8) 100 (44.2) 124 (35.1)
 T2 19 (14.8) 40 (17.7) 59 (16.7)
 T3 36 (28.1) 27 (11.9) 63 (17.8)
 T4 41 (32.0) 59 (26.1) 100 (28.2)
Lymph node metastasis (yp/p): n (%)
 N0 70 (54.7) 130 (57.5) 200 (56.5)
 N1 20 (15.6) 39 (17.3) 59 (16.7)
 N2 20 (15.6) 35 (15.5) 55 (15.5)
 N3 18 (14.1) 22 (9.7) 40 (11.3)
Stage (yp/p): n (%)
 CR 8 (6.3) 0 (0) 8 (2.3)
 Stage I 36 (28.1) 113 (50.0) 149 (42.1)
 Stage II 43 (33.6) 58 (25.7) 101 (28.5)
 Stage III 41 (32.0) 55 (24.3) 96 (27.1)
Median follow-up period (month) 40.9 45.4 43.8
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chemotherapy after a recurrence of the disease was 
found. The median SAR and OS in these 33 patients 
were 5.3 and 20.2 months, respectively. In contrast, eight 
(88.9  %) of the nine patients diagnosed with peritoneal 
recurrence on the basis of probe-laparoscopic findings 
underwent chemotherapy, resulted in median SAR and 
OS of 12.0 and 29.6  months, respectively. The SAR of 
patients with peritoneal recurrence detected by probe 
laparoscopy was significantly longer than that detected 
by CT (p  =  0.010). There was no significant difference 
between the OS of patients with peritoneal recurrence 
detected by probe laparoscopy and that detected by CT 
(p = 0.142).
Risk factors for peritoneal recurrence
Multivariate analyses demonstrated that age [odds ratio 
(OR), 1.709; 95 % confidence interval (CI), 1.075–2.715; 
p = 0.023], vascular invasion (OR 2.134; 95 % CI 1.227–
3.714; p = 0.007), a tumor size ≥70 mm (Aoyama et al. 
2012) (OR 1.796; 95 % CI 1.084–2.975; p = 0.023), undif-
ferentiated histological tumor type (OR 2.057; 95  % CI 
1.242–3.404; p  =  0.005), use of preoperative chemo-
therapy (OR 1.789; 95  % CI 1.137–2.814; p  =  0.012), 
yp/pT4 (OR 2.595; 95  % CI 1.545–4.359; p  <  0.001), 
and yp/pN3 (OR 4.113; 95 % CI 2.434–6.947; p < 0.001) 
were independent risk factors associated with peritoneal 
recurrence (Table 4). Peritoneal recurrence-free survival 
curves according to yp/pT4 and yp/pN3 are shown in 
Fig. 4. A significant difference was observed between per-
itoneal recurrence-free survival curves of ypN3 and pN3 
(p = 0.002).
Discussion
In this study, we analyzed long-term outcomes and 
recurrence patterns in patients who underwent an R0 
resection using LG-D2 for cStage ≥ IB gastric cancer. The 
5-year survival rates stratified by yp/pStage in this study 
were slightly lower than those in previous LG studies 
(Kim et al. 2010), this may be partly because 128 patients 
(36.2 %) who underwent PC were included in this study. 
The 5-year survival rate following a total gastrectomy has 
been shown to be lower than that following a distal gas-
trectomy (Maruyama et al. 1991; Isobe et al. 2011) at least 
partly because a total gastrectomy is more commonly 
performed in patients with large gastric cancer (Im et al. 
2012) than distal gastrectomy. Actually, in this study, the 
proportion of patients who underwent LTG out of all 
patients who underwent LG was 28.9 %, which is higher 
Fig. 1 Survival curve according to gastric cancer disease stages. 
Stage I, yp/pstages IA and IB; Stage II, yp/pstages IIA and IIB; and Stage 
III, yp/pstages IIIA, IIIB, and IIIC
Table 2 Recurrence patterns and survival times (n = 86)
OS overall survival, RFS recurrence-free survival, SAR survival after recurrence
Recurrence pat‑
tern








51 59.3 16.6 6.2 24.8
Hepatic  
metastasis
17 19.8 9.8 8.1 21.4
Hematogenous 
metastasis







10 11.6 14.5 18.7 35.0
 Distant lymph 
node
(10)
 Local lymph 
node
(0)
Table 3 Multiple patterns of metastasis at the initial recur-
rence (n = 8)
Recurrence pattern  
(dominant site)
Synchronous metastatic site N
Peritoneal metastasis Distant lymph node 3
Ovarium 2
Lung 1
Hepatic metastasis Brain 1
Lymph node metastasis Lung 1
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Fig. 2 Relationship between recurrence patterns and gastric cancer disease stages. a Recurrence rate according to the recurrence pattern and 
disease stage. The recurrence rate of peritoneal (p < 0.001) and hepatic (p < 0.001) metastasis increased concurrently with increase in yp/pStage. b 
Comparison of the recurrence rate according to yp/pT and yp/pN factors
Fig. 3 RFS curves according to the yp- and p-Stage. a RFS curves according to the p-Stage. b RFS curves according to the yp-Stage
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than that in other previous LG reports, (<10  %) (Kim 
et al. 2010, 2012) and is comparable with that mentioned 
in OG reports (20–40  %) (Maruyama et  al. 1991; Isobe 
et al. 2011; Sakuramoto et al. 2007; Sasako et al. 2008).
Regarding the proportion of initial recurrence patterns, 
on the one hand, there was a considerable difference in 
locoregional lymph node metastasis and local recurrence 
between this study (0  %) and previous studies (present 
study versus previous studies: locoregional lymph node 
metastasis, 0 versus 8–22  %; local recurrence 0 versus 
8–54  %) (Sasako et  al. 2008; Lee et  al. 2014; D’Angelica 
et al. 2004; Tajima et al. 2004), suggesting that the quality 
of our LG-D2 is acceptable. On the other hand, the fre-
quency of peritoneal metastasis was remarkably higher 
(present study vs. previous studies: 59.3 vs. 29–38  %). 
This may be partly because we readily performed probe 
laparoscopy to determine the presence of a peritoneal 
recurrence once a tumor recurrence was suspected (e.g., 
elevation of serum tumor marker levels, despite the 
absence of overt recurrence in imaging findings). The 
use of probe laparoscopy to observe the abdominal cav-
ity following LG must be easier than that following OG 
since adhesions in the abdominal cavity after LG are 
less severe. Therefore, we performed probe laparoscopy 
without any hesitation when a peritoneal recurrence was 
suspected but could not be determined via imaging stud-
ies. In fact, extensive adhesions were not observed in any 
patient enrolled in this study, and probe laparoscopy was 
safely performed in all 11 cases. Then, the site of recur-
rence was identified in all patients in this study, although 
previous studies regarding the long-term outcomes fol-
lowing OG demonstrated recurrence rates at 14–46 % at 
unknown sites (Maruyama et al. 1991; Isobe et al. 2011; 
Otsuji et al. 2004), indicating that a definitive diagnosis of 
peritoneal recurrence by imaging alone is difficult (Shim 
et al. 2011; Kim et al. 2009). Moreover, in this study, the 
SAR of a peritoneal metastasis diagnosed by probe lapa-
roscopy was extended compared with that diagnosed by 
CT. Thus, under excellent local control via LG-D2, peri-
toneal recurrence is expected to be an overwhelmingly 
dominant recurrence pattern as long as peritoneal metas-
tasis is the most common cause of death in gastric cancer 
patients; this suggests that the active use of probe lapa-
roscopy potentially promotes an accelerated detection 
of tumor recurrence, particularly occult tiny peritoneal 
Table 4 Risk factors for peritoneal recurrence
CI confidence interval, OR odds ratio
Variables Category Multivariate
OR 95 % CI p value
N factor yp/pN3 4.113 2.434–6.947 <0.001
T factor yp/pT4 2.595 1.545–4.359 <0.001
Histological type Undifferentiated 2.057 1.242–3.404 0.005
Vascular invasion Positive 2.134 1.227–3.714 0.007
Tumor size >70 mm 1.796 1.084–2975 0.023
Preoperative  
chemotherapy
Yes 1.789 1.137–2.814 0.012
Age ≥65 y.o. 1.709 1.075–2.715 0.023
Fig. 4 Peritoneal recurrence-free survival curves according to yp/pT4 and yp/pN. a Comparison of peritoneal recurrence-free survival curves 
according to ypT4 and pT4. b Comparison of peritoneal recurrence-free survival curves according to ypN3 and pN3
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metastasis. Further study is warranted to verify whether 
early detection of tumor recurrence leads to an improve-
ment in long term outcomes or not.
In this study, the peritoneal recurrence rate increased 
concurrently with increases in yp/pStage. Actually, in the 
present study, the peritoneal recurrence rates were 39 % 
in cases of yp/pT4 disease and 52 % in cases of yp/pN3 
disease, which were comparable with those reported in 
the previous OG studies (43.7–44.9 % for T4 and 37.4–
54.0  % for N3) (Aoyama et  al. 2012; D’Angelica et  al. 
2004; Tajima et al. 2004; Lee et al. 2014). In addition, in 
this study, a multivariate analysis demonstrated that T4, 
N3, a tumor size ≥70 mm, vascular invasion, and undif-
ferentiated tumor type were independent risk factors for 
peritoneal metastasis following LG-D2. Similar results 
have been reported in previous OG studies (Aoyama 
et al. 2012; Lee et al. 2014), which reported that a tumor 
size ≥70 mm, T4, N3, and vascular invasion were predic-
tive factors for peritoneal metastasis following OG. Thus, 
the incidence and predictors of peritoneal metastasis 
after LG-D2 appear to be comparable with those of peri-
toneal metastasis after OG.
It was possible that a negative conversion from P1 or 
Cy1 to P0 or Cy0 occurred because of PC and remained 
undetected because a staging laparoscopy was not per-
formed for all patients before PC in this study. Thus, 
Stage IV gastric cancer could have potentially migrated 
to other ypStages after PC. This may be one of the rea-
sons for the relatively high rate of peritoneal recurrence 
compared with other recurrence patterns in this study. 
Furthermore, the peritoneal recurrence-free survival 
curve of ypN3 was significantly inferior compared with 
that of pN3. This suggested that ypN3 patients need care-
ful follow up for peritoneal recurrence particularly.
There are some limitations to this study. First, this 
study was conducted in a retrospective manner. Second, 
the sample size was relatively small. Third, use of preop-
erative chemotherapy may have positively or negatively 
affected OS and RFS since the beginning date of OS and 
RFS was defined as that of the initial surgery but not the 
initial diagnosis.
In conclusion, at least under good LG-D2 local control, 
the oncological effect of LG-D2 was comparable with that 
of OG. As long as the recurrence occurs mostly on the 
peritoneum following LG-D2, probe laparoscopy, which 
is compatible with the status after LG causing less exten-
sive intraabdominal adhesion, should be actively used to 
detect minimal peritoneal recurrence after LG-D2.
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